Johnson Thomas, MD
Endocrinology, Diabetes & Metabolism · East Meadow, NYNPI 1922231331
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,741 of the $51,452 with a category attached, or 92.8%. Novo Nordisk accounts for 97.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $17,958 and has fallen 98.4% since, to $280 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $352.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$50K
- Amgen$518
- Dexcom, Inc.$419
- Medtronic$126
- AstraZeneca$110
- Abbott$93
- plus $270 from 12 others
Across 90 payments — averaging $1364.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$77K
- Argenx US, Inc.$35K
- Dexcom, Inc.$11K
What the payments were for
- Speaking & faculty fees$47,74193%
- Travel & lodging$7932%
- Food & beverage$2,8496%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $49,916 |
| Amgen(2 entities) | 10 | $518 |
| Dexcom, Inc. | 68 | $419 |
| Medtronic | 2 | $126 |
| AstraZeneca | 2 | $110 |
| Abbott | 6 | $93 |
| Sequel Med Tech, LLC | 3 | $46 |
| Kyowa Kirin, Inc. | 1 | $31 |
| Insulet Corporation | 1 | $30 |
| Pfizer | 2 | $29 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Tandem Diabetes Care, Inc. | 2 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Globus Medical | 1 | $15 |
| AbbVie | 1 | $14 |
| BETA Bionics, Inc. | 1 | $8 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$36,122
- Ozempic$11,449
- TEPEZZA$382
- MINIMED 780G$111
How this compares
$51,452 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 357 | $602,605 |
| JardianceEmpagliflozin | 359 | $349,005 |
| MounjaroTirzepatide | 147 | $214,567 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 57 | $162,728 |
| TrulicityDulaglutide | 80 | $112,966 |
| FarxigaDapagliflozin Propanediol | 84 | $82,325 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $70,817 |
| ForteoTeriparatide | 13 | $60,246 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 246 | $49,827 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $48,399 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $46,717 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $43,137 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $33,128 |
| Levothyroxine Sodium | 729 | $33,056 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $30,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $49,916 | $633,963399 claims |
| AstraZenecaFarxiga | $110 | $82,32584 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $23 | $33,12817 claims |
| AmgenProlia | $518 | $25,69715 claims |
| AbbVieSynthroid, Armour Thyroid | $14 | $5,95279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in East Meadow
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
- Philip OtterbeckStaten Island$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.